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Identification and characterization 
of aspartyl-tRNA synthetase 
inhibitors against Mycobacterium 
tuberculosis by an integrated 
whole-cell target-based approach
Ramón Soto1, Esther Perez-Herran2, Beatriz Rodriguez2, Bogdan M. Duma3,  
Monica Cacho-Izquierdo2, Alfonso Mendoza-Losana2, Joel Lelievre2, David Barros Aguirre2, 
Lluis Ballell2, Liam R. Cox3, Luke J. Alderwick1 & Gurdyal S. Besra  1
Mycobacterium tuberculosis, the causative agent of tuberculosis, has surpassed HIV as the leading cause 
of death due to an infectious disease worldwide, being responsible for more than 1.5 million deaths 
in low-income countries. In response to a pandemic threat by drug resistant strains, the tuberculosis 
research community is searching for new chemical entities with novel mechanisms of action to avoid 
drug resistance and shorten treatment regimens using combinatorial chemotherapy. Herein, we have 
identified several novel chemical scaffolds, GSK97C (spiro-oxazolidin-2-one), GSK93A (2-amino-1,3-
thiazole, GSK85A and GSK92A (enamides), which target M. tuberculosis aspartyl-tRNA synthetase (Mt-
AspRS), an essential component of the protein synthesis machinery of tuberculosis, using a whole-cell 
target-based screening strategy against a genetically modified Mycobacterium bovis BCG strain. We also 
provide further evidence of protein inhibition and inhibitor profiling through a classical aminoacylation 
reaction and a tRNA-independent assay, respectively. Altogether, our results have identified a number 
of hit new molecules with novel mechanism of action for further development through medicinal 
chemistry as hits and leads.
Tuberculosis (TB) ranks first as the leading cause of death due to an infectious disease worldwide, overcom-
ing HIV1. It represents a major threat to global health with one-third of the world’s population infected with 
latent tuberculosis, and multi-drug resistant (MDR) and extensively drug resistant (XDR) strains posing a sig-
nificant potential threat to health care systems if left unaddressed. To effectively treat patients with MDR-TB, a 
24-month-treatment regimen with second-line drugs, such as aminoglycosides and fluoroquinolones is needed, 
which unavoidably increases pill burden and potential side effects due to nephrotoxicity and damage to the cen-
tral nervous system2. In order to achieve effective eradication of MDR and XDR-TB safer and more effective drugs 
are urgently needed with entirely novel mechanism of action3.
Phenotypic high-throughput screening (HTS) strategies against Mycobacterium tuberculosis have provided 
many promising new hits, representing a shifting strategy from classical target-based approaches4. Whole genome 
sequencing (WGS) of spontaneous resistant isolates generated against HTS hits in vitro has proven to be a valid 
initial starting point for target identification5. The discovery of TMC2076,7, now licensed as the FDA-approved 
drug bedaquiline8, was one of the first hits to be characterised using this approach of WGS of resistant isolates, 
highlighting the success of phenotypic screening campaigns9. However, further detailed biochemical and genetic 
evidence is required to elucidate the precise mode of action of small molecule hits as exemplified by the recent 
studies of inhibitors targeting MmpL310–12.
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Aminoacyl-tRNA synthetases have extensively been studied by many academic research groups to elucidate 
the kinetics of their two-step reaction mechanism13,14, their specificity towards their cognate amino acid and 
tRNA15 and their evolution16. Their utility as the target of anti-infective agents is demonstrated by the use of the 
clinically approved isoleucyl-tRNA inhibitor, pseudomonic acid A17, although drug discovery efforts against these 
targets has remained challenging due to: (I) the lack of translational whole-cell inhibitory activities, (II) off-target 
effects due to ATP competitiveness and (III) poor pharmacokinetic profiles18. A rhodanine compound was pre-
viously identified to target the aspartyl-tRNA synthetase of TB by WGS approaches19, which was then biochem-
ically validated in a tRNA-independent assay20, encouraging further screening campaigns to find more potent 
and chemically tractable hits against this target. Herein, we have identified Mt-AspRS inhibitors by a whole-cell 
target-based screening of the so-called TB box21, a GSK library of 11,000 compounds (previously assessed against 
M. tuberculosis H37Rv) against the surrogate Mycobacterium bovis BCG strain genetically engineered to consti-
tutively express the TB AspRS open-reading frame in a replicative pMV261 plasmid. Combining whole-cell and 
target-based screening methods allows the discovery of new chemical entities with potential to shorten early drug 
discovery programmes.
Results and Discussion
Identification of novel M.tb AspRS inhibitors by a whole-cell target-based screening assay. In 
this study we report the identification of a number of biochemically validated Mt-AspRS inhibitors identified 
using a target-based whole-cell screening assay in Mycobacterium bovis BCG genetically modified to constitu-
tively express the Mt-AspRS open-reading frame. The GSK TB box compound collection of 11,000 compounds21 
was used at three independent concentrations (0.5, 2.5 and 12 μM) and initial hits were confirmed based on inhi-
bition shift between the two strains (calculated as % inhibition of M. bovis BCG pMV261 (empty plasmid) minus 
% inhibition of M. bovis BCG pMV261::Mt-AspRS [based upon duplicate data]) on ActivityBase (IDBS). Assay 
quality was monitored in an inter-plate manner with the statistical Z′, the gold standard to assess assay quality 
and reproducibility in HTS assays22. Plates with Z′ values below 0.4 were discarded for further analysis due to 
poor assay robustness.
Initial hits (250) were cherry-picked for further validation in a dose-response assay at a concentration range 
of 0.1 up to 100 μM to assess whole-cell potency and confirmation of whole-cell target-engagement (MIC50 shift) 
using the previously reported rhodanine entity as a tool control compound (Fig. 1). Compounds were tested in 
duplicate in an inter-plate manner and Sigmoidal dose-response curves were fitted to each data set using TIBCO 
Spotfire for analysis and data visualization. This resulted in the identification of 11 compounds with a minimum 
inhibitory concentration (MIC) shift >1. A table showing whole-cell target engagement is presented in the sup-
plementary section (S1).
Biochemical characterization of Mt-AspRS. Due to potential pathway-related effects caused by tar-
get overexpression23, biochemical evidence of protein inhibition is essential to further validate on-target inhib-
itory activities against a given target. In order to mimic physiological conditions we have utilized a classical 
tRNA-based aminoacylation reaction with Mt-AspRS in a 96-well-format to assess inhibitor potency and guide 
future hit-to-lead medicinal chemistry programmes against this target. The assay length and enzyme concen-
tration were adjusted in order to obtain an initial rate. The assay mixture was sampled at each time-point and 
precipitable radioactivity was quantified by scintillation counting. Background counts corresponding to free radi-
olabelled aspartic acid were subtracted at each data point and plotted over the time course of the assay (Fig. 2). For 
Figure 1. Dose-response in vitro activity curve of the tool rhodanine compound (GSK13A) showing 
target engagement between a pMV261::Mt-AspRS overexpressor M.bovis BCG strain (solid squares) and 
an empty pMV261 plasmid-containing M.bovis BCG strain (solid circles). Raw luminescence values from 
wells containing GSK13A (0.1–100 μM) were standardised to the positive (cells in 1% DMSO) and negative 
(7H9 media) control for cell growth. Processed data (percentage inhibition) was then plotted against each 
inhibitor concentration on Spotfire for MIC determination. Note the absence of inhibitory activities against the 
overexpressor strain at high compound concentrations, confirming resistance upon target overexpression.
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substrate dose-response studies, KM values are shown in Table 1 obtained as the mean ± SD of two duplicate sets 
obtained from hyperbolic Michaelis-Menten curves fitted to data obtained from tRNA and ATP dose-response 
studies. L-Asp KM values were obtained from the IC50 of a Sigmoidal curve minus the total concentration of 
radiolabelled aspartic acid employed in an isotopic dilution assay. Since a substrate with KM in the low micro-
molar range do not contribute to the increase in enzyme velocity, the concentration of radiolabelled L-Asp was 
subtracted from the IC50 value of the Sigmoidal curve for an accurate determination (Fig. 3).
Biochemical validation of screening hits against Mt-AspRS. In this study two active novel chemical 
families (GSK93A and GSK97C, Fig. 4) previously identified in the target-based HTS assay using M. bovis BCG 
over-expressing AspRS from M.tb were validated when interrogated for potency against isolated enzyme in an 
aminoacylation reaction. Structural details and physicochemical and biological properties of these hits, including 
MIC values against BCG strains and HepG2 cell lines, biochemical IC50 and physicochemical data are briefly 
summarised in the supplementary section. In vitro biochemical dose-response validation assays were performed 
at 0.2 μM Mt-AspRS and matching apparent KM values of L-Asp and tRNA while keeping ATP at a saturating 
concentration. Compound stocks were made as 10 mM solutions in 100% DMSO, diluted in a 1:3 fashion and 
dispensed into clear 96-well-polystetyrene plates up to a final concentration of 100 μM. The highest concentration 
of DMSO and CHAPS used in the assay were 1% and 0.5%, respectively, and precipitable radioactivity was trans-
ferred onto GF/C filter plates for scintillation counting. Raw data was standardized to the positive and negative 
enzyme activity controls and plotted versus the logarithm of the inhibitor concentration on Graph Pad Prism for 
IC50 determination.
Medium throughput target-based screening assay against GSK97C, GSK87A and GSK93A ana-
logues. As part of a preliminary approach to initial medicinal chemistry optimization efforts and therefore 
find chemical scaffolds with improved biological and physicochemical profiles, we performed a structure-based 
analogue search of these newly identified Mt-AspRS hits in the GSK 2 million compound collection to identify 
structurally-related hits that could be screened against Mt-AspRS in a target-based format. After attempts to min-
iaturise the tRNA-based assay into a 384-compatible SPA beads-based assay failed due to background inconsist-
ency, we decided to employ a miniaturised tRNA independent assay optimised for HTS purposes. Surprisingly, 
two novel chemical entities, analogues of the inhibitor GSK87A previously identified in the whole-cell 
target-based AspRS overexpressor assay, were identified when a small library of analogues of the three validated 
hits were interrogated for their potency in the aminoacylation reaction at concentrations ranging from 0.005 
up to 100 μM). Reagent stability was previously assessed over the overall period of the assay and robustness was 
monitored in an inter-plate manner (Z′ > 0.4). Interestingly, the parent compound GSK87A had failed to show 
potency in the biochemical validation assays against Mt-AspRS. However, two analogues of GSK87A (Fig. 5) were 
confirmed as Mt-AspRS inhibitors with IC50 values in the low micromolar range. The structures, biological and 
physicochemical properties are provided in the supplementary section (S2).
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Figure 2. Time-course of the aminoacylation activity monitored using the standard TCA precipitation method 
at several Mt-AspRS concentrations. Background radioactive counts (corresponding to residual L-Asp in the 
absence of enzyme) were subtracted and data converted to amount of product (aspartyl-tRNA) over the time-
course of the assay. The data was then plotted on GraphPad Prism 7.0 for the determination of the initial rate, 
which can be shown during the first 15 minutes of the aminoacylation reaction. 0.2 (triangles), 0.5 (circles) and 
1 μM (inverted triangles).
Varied Substrate Unvaried substrates Km (app) (µM)
L-Asp ATP (500 µM), tRNA (1 mg/ml) 13.8 ± 9.6
tRNA ATP (500 µM), L-Asp (900 µM) 0.40 ± 0.22
ATP tRNA (1 mg/ml), L-Asp (900 µM) 208.85 ± 8.41
Table 1. Summary of the apparent KM values for Mt-AspRS determined under Michaelis-Menten conditions. 
Data is expressed as the mean ± standard deviation of two independent replicates and the correlation coefficient 
is provided as a measure of goodness of fit for each of the curves.
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Mechanistic characterization of novel Mt-AspRS inhibitors. Due to the importance to assess 
off-target inhibitory activities early on in drug discovery projects it is essential to gain mechanistic insights into 
compound binding, particularly when targeting proteins with universally conserved ATP binding sites, such 
as kinases24 or aminoacyl-tRNA synthetases25. Despite the apparent loss in potency observed for GSK97C 
(potentially due to compound instability in storage conditions) we show here how these inhibitors display 
non-competitive binding mechanism against Mt-AspRS with respect to a β-γ-methyladenosine triphosphate 
substrate as an ATP surrogate in a tRNA-independent reaction (Fig. 6), suggesting that the compounds interfere 
with tRNA aminoacylation in an allosteric-binding manner, away from the antiparallel beta-sheet ATP-binding 
pocket of class II aminoacyl tRNA synthetases.
Conclusions
The availability of new chemical scaffolds with sufficient whole-cell and on-target inhibitory activities displaying 
novel modes of action represents a promising starting point in early TB drug discovery efforts. Traditionally, drug 
discovery efforts with aminoacyl tRNA inhibitors had been limited due (I) poor pharmacokinetic properties, 
(II) off-target effects caused by competitive binding mechanisms18 or (III) lack of penetration through bacterial 
membranes, the latter explaining the shifting strategy from target-based to whole-cell phenotypic approaches. 
We have expanded the chemical space available against Mt-AspRS that had traditionally been limited by these 
unspecific, ATP-competitive binding compounds or insufficient whole-cell inhibitory activities, further proving 
the versatility of Mt-AspRS as potential target for tuberculosis drug discovery. Diversifying the pipeline with 
inhibitors with novel modes of action is essential to ensure the overall survival of TB drug discovery projects with 
the potential to reach in vivo stages. Moreover, the success of integrating whole-cell and target-based screening 
Figure 3. Substrate dependence of Mt-AspRS activity. (A) Sigmoidal dose-response curve was fitted to the 
isotopic dilution of L-Asp and KM was determined as the IC50 minus the concentration of radiolabelled L-Asp. 
For (B,C), hyperbolic Michaelis-Menten curves were fitted to obtain apparent KM values for ATP and tRNA, 
respectively. Each experiment was done keeping two out of three substrates at saturation and KM values are 
reported as the mean ± the standard deviation of two duplicates.
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strategies against other targets has previously been demonstrated, allowing the straightforward identification of 
small molecules against virtually any essential target with acceptable druggability features26. This has the potential 
to shorten the preclinical turnaround times of drug development projects. In this context, we have shown that 
expanding the chemical space available for Mt-AspRS inhibitors can expand existing possibilities for drug devel-
opment by exploiting new hits with novel modes of action and mechanistic features, expanding the pipeline of 
available preclinical antitubercular agents. The identification of inhibitors targeting conserved binding sites that 
retain selectivity has been shown to be achievable27 although as we show here, mechanistic studies are needed to 
derisk potential ATP-competitive inhibitors. However, despite the availability of increasing numbers of preclinical 
candidates for the treatment of TB, it is important to consider that small molecule drug discovery is not enough 
to tackle the epidemic. Combinatorial chemotherapy needs to be complemented with rapid diagnostic tools and 
effective prophylaxis to contain the spread of drug resistant strains. In addition, improved health care is needed in 
low-income countries so that tuberculosis patients can effectively access new medicines. Altogether, our results 
represent another step toward the final eradication of TB by expanding the chemical space available against tRNA 
synthetases of this organism.
Methods
Ethics statement. All experiments were performed in accordance with the relevant ethical guidelines and 
regulations approved by the University of Birmingham and Diseases of the Developing World (DDW-GSK) 
Ethical Committees where required and there are no other ethical issues to report.
Figure 4. Structures and in vitro potency of novel antimycobacterial compounds that target the essential Mt-
AspRS. (A) Structures of compounds identified through a target-based whole-cell screening assay against a M. 
bovis BCG over-expressing AspRS from Mtb. (B) Dose-response curves of the effect of compounds GSK97C 
and GSK93A against Mt-AspRS in the amino acylation reaction. Reaction mixtures were added to increasing 
compound concentrations (0.005–100 μM) and precipitable radioactivity quantified by scintillation counting 
in a Microbeta Trilux 1450. Raw cpm values were standardised to the maximum (100%) and minimum (0%) 
control for enzyme activity (with and without enzyme, respectively), plotted over the logarithm of inhibitor 
concentration and fitted to Sigmoidal dose-response curves for IC50 determination. Each inhibitor was tested 
in duplicates and the IC50 is reported as the mean of two replicates.
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Figure 5. Structures and in vitro potency of newly identified antitubercular analogues of GSK97A targeting 
Mt-AspRS. (A) Structures of chemical entities identified in a target-based screening of structural analogues of 
several whole-cell screening hits in a tRNA-independent aminoacylation reaction. (B) Dose-response curves of 
the effect of compounds GSK92A and GSK85A against Mt-AspRS in the tRNA-independent amino acylation 
reaction. Raw fluorescence values corresponding to initial rates of the enzymatic reaction were normalised to 
the positive and negative control for enzyme activity (plus and minus enzyme, respectively) and plotted versus 
the logarithm of inhibitor concentration on GraphPad Prism 6.0 for IC50 determination.
Figure 6. Reversible and non-competitive mode of inhibition of GSK97C (A) and GSK93A (B) against Mt-
AspRS. β-γ-methyladenosine triphosphate (ADPCP, 0–4000 μM) and inhibitor (DMSO, 50 and 100 μM) were 
tested in duplicate in a microtiter 384-well-plate and the initial enzyme velocity (raw fluorescence units per 
minute) was plotted against each of the inhibitor concentrations to assess substrate competitiveness with regard 
to ADPCP.
www.nature.com/scientificreports/
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Strains and culture conditions. Whole-cell screening experiments were conducted using M.bovis BCG 
that had been previously transformed with a pMV261 containing the Mt-AspRS20. Selected transformants were 
grown using 7H9 media supplemented with 0.025% Tween, 10% ADC (Albumin, Dextrose, Catalase) and kan-
amycin (25 μg/ml).
Whole-cell target-based screening. The GSK TB box collection was screened for Mt-AspRS inhibitors 
based on resistance upon Mt-AspRS overexpression. We selected three different concentrations (0.5, 2.5 and 
12.5 μM) based on compound potency in order not to miss any potential hit. A standard inoculum size of 104 cells 
in 25 μL was added into each assay well of a 384-well-plate with white opaque walls using a MultidropTM Combi 
dispenser (Thermo Scientific). To control evaporation, plates were individually sealed with parafilm, covered 
with aluminium foil and stored in plastic boxes inside a 37 °C and 5% CO2 incubator with humidity control. At 
day 7, reconstituted Bac-titer GLO reagent (25 μL) were added into each assay well, which causes cell lysis and 
allows the luminescent detection of ATP consumption, briefly shaken for 8 minutes and read for luminescence 
using a Spectra Max M5 reader. Raw luminescence values were standardized to cell survival percentages using 
positive and negative controls for cell growth. The effect of a given inhibitor was calculated as: % inhibition = 100* 
((data- control 1)/(control 2- control 1)) where control 1 = maximum activity (DMSO only; uninhibited growth), 
and control 2 = bacterial growth completely inhibited (by treatment with 10 μM rifampicin). Assay performance 
statistics (signal to background ratio and Z′) were calculated using templates in ActivityBase XE (ID Bussines 
Solutions Ltd, Surrey, UK). Dose-response confirmation studies were performed at a concentration range 0.1 
up to 100 μM in a 1:3 dilution fashion and raw luminescence values were standardized to the maximum and 
minimum percentage of inhibition as stated for single-shot experiments. Dose-response curves were obtained on 
Tibco Spotfire and whole-cell target engagement confirmed by the MIC shift, reported here as the ratio between 
the mean of the MIC values for each strain.
Biochemical characterization of recombinant Mt-AspRS. Pure, recombinant Mt-AspRS was 
obtained as previously described20. To establish accurate inhibitor potency, prior biochemical characterization is 
essential to obtain optimised substrate concentrations for aspartic acid (L-Asp), adenosine triphosphate (ATP) 
and tRNA. For speed and convenience, a pool of commercially available tRNA was used since a high degree of 
sequence identity is shared between E. coli and M. tuberculosis tRNA molecules. The Mt-AspRS functional char-
acterisation was developed using a classical TCA precipitation method in standard 96-well-polystyrene plates. 
The aminoacylation reaction was performed in a final assay mixture of 80 μL consisting of 20 mM HEPES buffer 
pH 7.7, 4 mM MgCl2, 50 mM KCl and a range of substrate and enzyme concentrations in order to determine 
the initial rate and the kinetic constants of the aminoacylation reaction. The values obtained in the experiments 
described below were therefore obtained under steady-state conditions following classical Michaelis-Menten 
guidelines for enzyme kinetic studies. For the determination of the initial rate of the aminoacylation reaction, 
several enzyme concentrations (0.2, 0.5 and 1 μM) were incubated at 37 °C in the presence of 1 mg/mL tRNA 
from E. coli 600 MRE, 15 μM L-Asp (200 mCi/mmol, Perkin Elmer) and 4 mM ATP. The reaction was quenched at 
several time points over a period of fifteen minutes with 50 μL of 10% TCA. When the time-course was complete, 
the plates were incubated at 4 °C during 30 minutes to allow for proper tRNA precipitation. The aminoacylated 
product was then transferred onto GF/C 96-well filter plates (Packard), extensively washed in an excess volume 
of TCA (10%), once with 95% ethanol and then dried under a heat lamp prior to scintillation counting in a 
Microbeta Trilux 1450 model, basically in accordance with the method previously described for classical studies 
of aminoacyl-tRNA synthetases28. For KM determination, varying substrate concentrations were assayed keeping 
the others at saturating concentrations. For L-Asp kinetic studies, a starter concentration of radiolabelled L-Asp 
of 15 μM was serially diluted with non-radioactive L-Asp to a final concentration of 900 μM where saturation was 
observed. The obtained data points were fitted to a Sigmoidal dose-response curve on Graph Pad Prism 7.0, and 
its IC50 value correSponds to the KM plus the concentration of radiolabelled L-Asp used in the assay.
Biochemical validation of screening hits. The IC50 dose response assays for each were performed at 
0.2 μM Mt-AspRS and matching apparent KM values of L-Asp and tRNA, while keeping ATP at a saturating con-
centration in order to filter out ATP-competitive inhibitors. Compound stocks were made as 10 mM solutions in 
100% DMSO and dispensed into 96-well-polystetyrene plates in a 1:3 dilution manner up to a final concentration 
of 100 μM. In the maximum (100% activity) and minimum (0% activity) controls similar DMSO concentrations 
were added to check the absence of solvent-related inhibition. The highest concentration of DMSO and CHAPS 
used in the assay were 1% and 0.5%, respectively. Precipitable radioactivity was transferred onto GF/C filter plates 
for scintillation counting.
Medium-throughput screening assay of a series of analogues in a tRNA-independent bio-
chemical assay. A number of structurally related analogues to GSK97C, GSK93A and GSK87A from the 
GSK TB box collection were evaluated in a dose-response manner (0.1–100 μM) in a 384-well black-bottom 
microplate-adapted ATP release assay optimised for HTS purposes. The reaction mixture consisted of 20 mM 
HEPES pH 7.6, 4 mM MgCl2, 50 mM KCl, 1 mM DTT, 2 mM ADPCP, 10 mM D-glucose, 0.5 mM NADP+, 10 mM 
L- Asp, 3 μg of yeast hexokinase and L. mesenteroides glucose-6- phosphate dehydrogenase mixture and 0.5 μM of 
Mt-AspRS in a final assay volume of 20 μL. The amount of coupled enzymes used was high enough to minimise 
assay intereference. Stock compounds were dispensed with the Echo 555 (Labcyte) into black bottom 384 plates 
(Greiner 781101) and were stored at −80 °C until needed. Enzymes and substrates were kept separately in two 
working solutions prepared at 2X the final assay concentrations. Reactions were triggered with the addition of 
substrate solution into plates pre-plated with enzyme and no-enzyme control wells. The assay was performed 
at room temperature and fluorescence values were continuously monitored in EnVision (Perkin Elmer) during 
www.nature.com/scientificreports/
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the period of the assay (4 minutes). Similar amounts of DMSO (1%) were added into control wells to check 
for absence of solvent-related inhibition. The raw data was normalised to the positive and negative controls for 
enzyme activity in Excel and was further processed in Excel and GraphPad Prism 6.0 for IC50 determination.
Mechanistic characterization of novel Mt-AspRS inhibitors. The inhibitory activities of GSK97C 
and GSK93A against Mt-AspRS was assessed at several β-γ-methyladenosine triphosphate (0–8000 μM) and 
inhibitor concentrations (DMSO, 50 and 100 μM) while keeping fixed amounts of L-Asp and PPi at saturat-
ing values (10*KM). The reaction was triggered with the addition of 10 μL of a 2X substrate mix solution to a 
384 black-bottom polystyrene plate (Corning) containing 10 μl of a 2X buffer solution with 1 μM Mt-AspRS in 
40 mM HEPES pH 7.6, 8 mM MgCl2 and 100 mM KCl. Plates were then briefly centrifuged and read on EnVision 
(Perkin Elmer) using NADPH fluorescence in the kinetic mode as the method of detection. Slopes corresponding 
to initial reaction rates were plotted versus substrate concentration for each inhibitor concentration and data 
points were fitted to standard hyperbolic Michaelis Menten curves on GraphPad Prism 6.0 for KM and VMAX 
determination.
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